S&P 500   5,070.24 (+0.01%)
DOW   38,926.04 (-0.37%)
QQQ   437.10 (+0.13%)
AAPL   181.03 (-0.07%)
MSFT   405.98 (-0.38%)
META   484.41 (+0.55%)
GOOGL   138.23 (+0.48%)
AMZN   174.17 (-0.32%)
TSLA   202.82 (+1.72%)
NVDA   785.05 (-0.74%)
NIO   5.83 (+3.19%)
AMD   176.43 (+0.24%)
BABA   77.71 (+1.57%)
T   16.55 (-0.30%)
F   12.03 (+0.67%)
MU   90.62 (+1.30%)
CGC   3.52 (+1.44%)
GE   153.87 (-0.58%)
DIS   108.06 (+0.35%)
AMC   4.62 (+3.82%)
PFE   26.95 (-0.85%)
PYPL   59.73 (+0.67%)
XOM   104.34 (+0.09%)
S&P 500   5,070.24 (+0.01%)
DOW   38,926.04 (-0.37%)
QQQ   437.10 (+0.13%)
AAPL   181.03 (-0.07%)
MSFT   405.98 (-0.38%)
META   484.41 (+0.55%)
GOOGL   138.23 (+0.48%)
AMZN   174.17 (-0.32%)
TSLA   202.82 (+1.72%)
NVDA   785.05 (-0.74%)
NIO   5.83 (+3.19%)
AMD   176.43 (+0.24%)
BABA   77.71 (+1.57%)
T   16.55 (-0.30%)
F   12.03 (+0.67%)
MU   90.62 (+1.30%)
CGC   3.52 (+1.44%)
GE   153.87 (-0.58%)
DIS   108.06 (+0.35%)
AMC   4.62 (+3.82%)
PFE   26.95 (-0.85%)
PYPL   59.73 (+0.67%)
XOM   104.34 (+0.09%)
S&P 500   5,070.24 (+0.01%)
DOW   38,926.04 (-0.37%)
QQQ   437.10 (+0.13%)
AAPL   181.03 (-0.07%)
MSFT   405.98 (-0.38%)
META   484.41 (+0.55%)
GOOGL   138.23 (+0.48%)
AMZN   174.17 (-0.32%)
TSLA   202.82 (+1.72%)
NVDA   785.05 (-0.74%)
NIO   5.83 (+3.19%)
AMD   176.43 (+0.24%)
BABA   77.71 (+1.57%)
T   16.55 (-0.30%)
F   12.03 (+0.67%)
MU   90.62 (+1.30%)
CGC   3.52 (+1.44%)
GE   153.87 (-0.58%)
DIS   108.06 (+0.35%)
AMC   4.62 (+3.82%)
PFE   26.95 (-0.85%)
PYPL   59.73 (+0.67%)
XOM   104.34 (+0.09%)
S&P 500   5,070.24 (+0.01%)
DOW   38,926.04 (-0.37%)
QQQ   437.10 (+0.13%)
AAPL   181.03 (-0.07%)
MSFT   405.98 (-0.38%)
META   484.41 (+0.55%)
GOOGL   138.23 (+0.48%)
AMZN   174.17 (-0.32%)
TSLA   202.82 (+1.72%)
NVDA   785.05 (-0.74%)
NIO   5.83 (+3.19%)
AMD   176.43 (+0.24%)
BABA   77.71 (+1.57%)
T   16.55 (-0.30%)
F   12.03 (+0.67%)
MU   90.62 (+1.30%)
CGC   3.52 (+1.44%)
GE   153.87 (-0.58%)
DIS   108.06 (+0.35%)
AMC   4.62 (+3.82%)
PFE   26.95 (-0.85%)
PYPL   59.73 (+0.67%)
XOM   104.34 (+0.09%)
NYSE:ZTS

Zoetis (ZTS) Stock Price, News & Analysis

$197.81
+0.77 (+0.39%)
(As of 10:39 AM ET)
Today's Range
$194.04
$197.86
50-Day Range
$183.46
$198.94
52-Week Range
$151.03
$201.92
Volume
349,893 shs
Average Volume
2.06 million shs
Market Capitalization
$90.57 billion
P/E Ratio
39.02
Dividend Yield
0.87%
Price Target
$224.33

Zoetis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
13.9% Upside
$224.33 Price Target
Short Interest
Healthy
0.65% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.75mentions of Zoetis in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$748,470 Sold Last Quarter
Proj. Earnings Growth
12.26%
From $5.79 to $6.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.78 out of 5 stars

Medical Sector

47th out of 942 stocks

Pharmaceutical Preparations Industry

17th out of 429 stocks


ZTS stock logo

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

ZTS Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
16 Best Dog Breeds For First Time Owners
ZTS Apr 2024 135.000 put
Zoetis (NYSE:ZTS) Given New $220.00 Price Target at Piper Sandler
Energy Storage Trend Ignites Frenzy Over Vanadium Supply
As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.
ZTS Jan 2026 160.000 call
4 Analysts Have This To Say About Zoetis
StockNews.com Downgrades Zoetis (NYSE:ZTS) to Buy
Zoetis Inc. (NYSE:ZTS) Q4 2023 Earnings Call Transcript
Company News for Feb 14, 2024
Q4 2023 Zoetis Inc Earnings Call
Zoetis Full Year 2023 Earnings: EPS Misses Expectations
Zoetis (ZTS) Q4 2023 Earnings Call Transcript
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
Zoetis stock slides on poor FQ4 earnings, guidance miss
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/1 Dividend
10/31/2023
Dividend Payable
12/01/2023
Ex-Dividend for 3/1 Dividend
1/18/2024
Last Earnings
2/13/2024
Today
2/26/2024
Dividend Payable
3/01/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
98978V10
Employees
14,100
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$224.33
High Stock Price Target
$260.00
Low Stock Price Target
$200.00
Potential Upside/Downside
+13.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$2.34 billion
Pretax Margin
34.36%

Debt

Sales & Book Value

Annual Sales
$8.54 billion
Cash Flow
$6.42 per share
Book Value
$10.87 per share

Miscellaneous

Free Float
457,180,000
Market Cap
$90.22 billion
Optionable
Optionable
Beta
0.88

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Zoetis was last updated on Wednesday, February 21, 2024 at 2:40 PM.

Pros

Here are some ways that investors could benefit from investing in Zoetis Inc.:

  • Zoetis Inc. is a leading company in the animal health industry, with a strong track record of developing innovative medicines, vaccines, and diagnostic products.
  • The company has a diverse portfolio of products that cater to both veterinarians, livestock producers, and pet owners, providing multiple revenue streams.
  • Recent developments in the animal health sector have increased demand for Zoetis Inc.'s products, leading to potential growth opportunities.
  • Zoetis Inc. has shown consistent financial performance, with a strong balance sheet and stable revenue streams.
  • The current stock price of Zoetis Inc. is competitive, offering investors a potentially attractive entry point.

Cons

Investors should be bearish about investing in Zoetis Inc. for these reasons:

  • While Zoetis Inc. has a strong position in the animal health industry, competition from other companies could impact market share and profitability.
  • Regulatory changes or disruptions in the supply chain could affect Zoetis Inc.'s ability to develop and distribute its products effectively.
  • Fluctuations in commodity prices or changes in consumer preferences could impact demand for Zoetis Inc.'s products, affecting revenue and profitability.
  • Investing in Zoetis Inc. carries inherent risks associated with the healthcare and pharmaceutical industry, including regulatory approvals and product recalls.
  • While the current stock price may be attractive, investors should consider the overall market conditions and potential risks before making investment decisions.














ZTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price target for 2024?

8 Wall Street research analysts have issued 12 month price targets for Zoetis' stock. Their ZTS share price targets range from $200.00 to $260.00. On average, they expect the company's stock price to reach $224.33 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2024?

Zoetis' stock was trading at $197.37 at the beginning of the year. Since then, ZTS shares have decreased by 0.2% and is now trading at $197.04.
View the best growth stocks for 2024 here
.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,960,000 shares, an increase of 7.6% from the January 15th total of 2,750,000 shares. Based on an average trading volume of 1,840,000 shares, the short-interest ratio is currently 1.6 days. Currently, 0.7% of the company's shares are short sold.
View Zoetis' Short Interest
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ZTS earnings forecast
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) posted its quarterly earnings results on Tuesday, February, 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.32 by $0.08. The company earned $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a trailing twelve-month return on equity of 51.25% and a net margin of 27.43%. The business's revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.15 EPS.
Read the conference call transcript
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Tuesday, February 6th. Stockholders of record on Friday, April 19th will be paid a dividend of $0.432 per share on Tuesday, June 4th. This represents a $1.73 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Thursday, April 18th.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.73 per share and currently has a dividend yield of 0.88%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 34.12%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 26.62% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share guidance of 5.740-5.840 for the period, compared to the consensus earnings per share estimate of 5.980. The company issued revenue guidance of $9.1 billion-$9.2 billion, compared to the consensus revenue estimate of $9.2 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?
Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.79%), State Farm Mutual Automobile Insurance Co. (3.56%), Capital International Investors (3.20%), Price T Rowe Associates Inc. MD (3.00%), Capital World Investors (1.97%) and Nuveen Asset Management LLC (1.43%). Insiders that own company stock include Glenn David, Gregory Norden, Heidi C Chen, Kristin C Peck, Robert Edward Kelly, Robert J Polzer, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
This page (NYSE:ZTS) was last updated on 2/27/2024 by MarketBeat.com Staff